share_log

派林生物(000403.SZ):截止目前来看集采对血液制品影响相对较小

Pacific Shuanglin Bio-Pharmacy (000403.SZ): So far, the impact of centralized procurement on blood products appears to be relatively small.

Gelonghui Finance ·  Aug 9 03:17

Pacific Shuanglin Bio-pharmacy (000403.SZ) stated during an investor relations event on August 9 that in 2022, Guangdong Province and ten other provinces in China conducted joint procurement, and in 2023, Hebei and 19 other provinces, including Jing-Jin-Ji, conducted joint procurement of immunoglobulin. In addition, there will be a joint procurement of fibrinogen in 2024. Overall, for products such as albumin and intravenous immunoglobulin, which are currently in short supply or in high demand, joint procurement has only a small impact on their prices. As for immunoglobulin and fibrinogen, which are relatively abundant, lower prices from joint procurement are beneficial for patients and also for increasing sales, with the overall impact on blood products remaining relatively minor as of now.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment